Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Rugo Highlights Latest Advances in TNBC Treatment

October 6th 2019

Hope S. Rugo, MD, discusses the latest advancements in the treatment landscape for patients with TNBC and highlights some data from clinical trials presented at the 2019 ESMO Congress.

Dr. Barrio on Neoadjuvant Chemo to De-Escalate Axillary Node Dissection in Breast Cancer

October 6th 2019

Andrea V. Barrio, MD, FACS, discusses how the use of neoadjuvant chemotherapy can help de-escalate axillary node dissection in select patients with breast cancer. Dissection can be a morbid procedure with longterm risks of lymphoma, impacting the quality of life for many patients.

Use of Neoadjuvant Endocrine Therapy Showcases Testing Capabilities in Breast Cancer

October 6th 2019

In breast cancer, neoadjuvant endocrine therapy shows promise in a variety of areas, including as an excellent testing platform, Ingrid A. Mayer, MD, MSCI, said in a presentation during the 2019 Lynn Sage Breast Cancer Symposium.

Trends in Pathologic Complete Response After Neoadjuvant Chemo in Breast Cancer

October 5th 2019

In contemporary breast cancer clinical practice, the correlation between achieving a pathologic complete response after neoadjuvant chemotherapy and significantly improved outcomes after chemotherapy has been well established. However, in a discussion at the 2019 Lynn Sage Breast Cancer Symposium, William J. Gradishar, MD, cautioned colleagues that there is more to the story when one looks at long-term data in these patients.

Dr. Morrow on Patient Selection for Nipple Sparing Mastectomy

October 5th 2019

Monica Morrow, MD, discusses the factors that impact the decision to use nipple sparing mastectomy versus conventional mastectomy in patients with breast cancer. The decision to use a nipple sparing approach in patients is dependent on 2 considerations. These relate to the cancer as well as cosmetic appearance of the breast.

Inflammatory Breast Cancer Has Diagnostic Challenges, Requires More Awareness

October 5th 2019

Naoto Tada Ueno, MD, PhD, FACP, discusses the diagnosis and treatment of patients with inflammatory breast cancer and highlights the biggest challenges in both diagnosing and treating this patient population.

Dr. King on Neoadjuvant Chemotherapy in Breast Cancer

October 5th 2019

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Womens Cancer Center, discusses the role of a multidisciplinary team when considering neoadjuvant chemotherapy (NAC) for patients with breast cancer.

Patient Selection Key When De-Escalating Radiation in Breast Cancer

October 5th 2019

Jonathan B. Strauss, MD, MBA, discussed the role of hypofractionated radiotherapy in patients with breast cancer and offered advice on treatment selection.

Multipronged De-Escalated Chemo Strategy Could Yield Best Results in HER2+ Breast Cancer

October 5th 2019

As more becomes known about the biology of HER2-positive early breast cancer, C. Kent Osborne, MD, says that a multipronged strategy is the best approach regarding de-escalating chemotherapy in this patient population.

Dr. Ganz on the Symptoms Related to Estrogen in Breast Cancer

October 5th 2019

Patricia Ganz, MD, discusses the symptoms related to estrogen hormones that can cause more implications for women with breast cancer, including menopausal symptoms such as hot flashes, vaginal dryness, trouble sleeping, and fatigue.

Dr. Van Zee on Prevention of Invasive Recurrence in Breast Cancer

October 4th 2019

Kimberly Van Zee, MD, discusses the importance of preventing invasive recurrence in patients with breast cancer at the 21st Annual Lynn Sage Breast Cancer Symposium.

Examining Major Breakthroughs Made in Breast Cancer in Milwaukee

October 2nd 2019

We traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Breast Cancer, which featured insights from key thought leaders at Carbone Cancer Center of the University of Wisconsin.

Duke Cancer Institute Faculty Describe Latest Efforts in Breast Cancer Research

October 1st 2019

Faculty from Duke Cancer Institute provide insight into the exciting breast cancer research being conducted at their institution.

Positive Abemaciclib Data Emerge for Chinese Women With HR+ Breast Cancer

September 30th 2019

A population of predominantly Chinese women with advanced hormone receptor–positive/HER2-negative breast cancer obtained significant benefits from treatment with the CDK4/6 inhibitor abemaciclib and endocrine therapy.

Dr. Slamon on OS Results of the MONALEESA-3 Trial in HR+/HER2- Breast Cancer

September 29th 2019

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the overall survival results of the phase III MONALEESA-3 trial in hormone receptor-positive, HER2-negative breast cancer.

PD-L1 Assays Demonstrate

September 29th 2019

An exploratory biomarker substudy of Impassion130 demonstrated clinical activity of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) in a subgroup of patients with triple-negative breast cancer who had immune cell PD-L1 expression by the SP142 immunohistochemistry assay, regardless of the site of the tumor sample.

Abemaciclib/Fulvestrant Improves Survival in HR+ Advanced Breast Cancer

September 29th 2019

The addition of the CDK4/6 inhibitor abemaciclib (Verzenio) to fulvestrant (Faslodex) led to a median 9.4-month overall survival benefit compared with fulvestrant with placebo in patients with hormone receptor–positive, HER2-negative advanced breast cancer who progressed on prior endocrine therapy.

Ribociclib/Fulvestrant Combo Improves OS in Advanced HR+ Breast Cancer

September 29th 2019

The combination of ribociclib and fulvestrant led to an approximate 28% reduction in the risk of death compared with placebo and fulvestrant in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Neoadjuvant Pembrolizumab Combo Prolongs pCR in Phase III TNBC Study

September 29th 2019

Neoadjuvant treatment with the combination of pembrolizumab and chemotherapy extended pathological complete response rates by 13.6 percentage points compared with chemotherapy alone for patients with early triple-negative breast cancer.

Trilaciclib Delivers "Unexpected" Survival Boost in TNBC

September 29th 2019

The investigational CDK4/6 inhibitor trilaciclib unexpectedly improved survival in metastatic triple-negative breast cancer despite failing to meet a safety-related primary endpoint.